Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group
Rattachement africain : us, jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. METHODS: We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (<500 000 JPY/month). RESULTS: The study included 1880 participants, 24% of whom were ≥ 75 years. Molecular targeted containing regimens were received by 78% of the patients. The most frequently used regimen was the doublet regimen (fluoropyrimidine with either oxaliplatin or irinotecan) plus bevacizumab (43%), followed by doublet plus cetuximab or panitumumab (21%). The cost of molecular targeted drugs-containing regimens (ranging from 85 406 to 843 602 JPY/month) is much higher than that of only cytotoxic drug regimens (ranging from 17 672 to 51 004 JPY/month). About 16% received high-cost treatments that included panitumumab-containing regimens and pembrolizumab (17% of patients aged ≤74 years and 11% of patients aged ≥75 years). CONCLUSION: About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group
- Date Crossref
- 29/08/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Cancer Center Division of Gastrointestinal Medical Oncology pays non établi dans la noticeOrganisation à but non lucratif
-
National Cancer Center Hospital East pays non établi dans la noticeÉtablissement de santé
-
Tokyo Medical and Dental University Health Science Research & Development Center pays non établi dans la noticeUniversité ou école supérieure
-
Japan Clinical Cancer Research Organization pays non établi dans la noticeStructure de recherche
-
Kyorin University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Gunma Prefectural Cardiovascular Center pays non établi dans la noticeÉtablissement de santé
-
Gunma Children's Medical Center pays non établi dans la noticeÉtablissement de santé
-
Gunma Prefectural Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Saitama International Medical Center pays non établi dans la noticeÉtablissement de santé
-
Saitama Medical University Department of Gastroenterological Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University of Tsukuba Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Aichi Cancer Center pays non établi dans la noticeÉtablissement de santé
Division of Gastrointestinal Medical Oncology — National Cancer Center, National Cancer Center Hospital East et Health Science Research & Development Center — Tokyo Medical and Dental University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.